SummaryRecent physiopathological data attribute to the platelets an ever more important role in the thrombogenesis. Therefore is the oral anticoagulant use only maintained is some definite conditions which have been indicated in this review.From the first statistical significant studies published, it appears that some platelet function inhibitors useful in clinical trials, are potent in some clinical cases and ineffective in others.It is still premature at present to give definitive conclusions about the real antithrombotic value of these drugs because most of the epidemiological studies are currently underway in different countries.It appears meanwhile that the combination of these two kinds of drugs (anticoagulants and platelet inhibitors) and«a fortiori»their grouping with a third agent like fibrinolysis activators can constitute a more effective approach of the thrombosis prophylaxis.